MedTrace Logo

Preservative-free Tafluprost/Timolol Fixed Combination: Morning vs Evening Dosing

NCT03612817 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2020-12-17

No results posted yet for this study

Summary

The ideal dosing for preservative-free tafluprost/timolol fixed combination remains to be elucidated. The present study compared the 24-hour intraocular pressure efficacy obtained with tafluprost/timolol given once in the evening with placebo once in the morning, versus that with the same fixed combination administered once in the morning with placebo given once in the evening in consecutive patients with open-angle glaucoma insufficiently controlled with branded, or generic latanoprost monotherapy.

Conditions

  • Glaucoma, Open-Angle

Interventions

DRUG

Tafluprost/timolol fixed combination

Evaluation of 24-hour pressure control with tafluprost/timolol given in the evening or morning

Sponsors & Collaborators

  • Santen Oy

    collaborator INDUSTRY

  • Aristotle University Of Thessaloniki

    lead OTHER

Principal Investigators

  • Theodoros Giannopoulos, MD · Aristotle University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2018-04-30
Completion
2018-07-31

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03612817 on ClinicalTrials.gov